Toronto Dominion Bank
PTGX icon

Toronto Dominion Bank’s Protagonist Therapeutics PTGX Stock Holding History

Toronto Dominion Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-349
Closed -$36.8K – 2433
2026
Q1 		$36.8K Buy
+349
New +$30.9K ﹤0.01% 1805
2025
Q4 		– Sell
-445,440
Closed -$36.5M – 2242
2025
Q3 		$29.6M Hold
445,440
– – 0.05% 335
2025
Q2 		$24.6M Hold
445,440
– – 0.04% 343
2025
Q1 		$21.5M Buy
445,440
+104,466
+31% +$4.38M 0.04% 315
2024
Q4 		$13.2M Buy
+340,974
New +$14.9M 0.02% 457

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Toronto Dominion Bank's PTGX Position: Q2 2026 in Review

Toronto Dominion Bank sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 349 shares — an estimated $36.8K sold.

Toronto Dominion Bank first reported a position in PTGX in Q4 2024 and held it in 5 quarters. The position peaked at $29.6M in Q3 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Toronto Dominion Bank reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Toronto Dominion Bank sold 349 Protagonist Therapeutics shares in Q2 2026, an estimated $36.8K.
  • Toronto Dominion Bank first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 5 quarters.
  • Toronto Dominion Bank's Protagonist Therapeutics position peaked at $29.6M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Toronto Dominion Bank's 13F filing for Q2 2026, filed 14 Aug 2026.